Cision PR Newswire

Akeso’s AK157D1 (B7-H3 ADC) Cleared for Phase I Trial in Solid Tumors, Adding a Third Differentiated ADC to Its Pipeline

HONG KONG, Aug. 21, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its investigational next-generation B7-H3-targeting antibody-drug conjugate (ADC), AK157D1, has received clinical trial clearance from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). The clearance allows initiation of...

China Liberal Education Holdings Limited Has Regained Compliance with Nasdaq’s Minimum Bid Price Deficiency

BEIJING, Jan. 13, 2025 /PRNewswire/ -- China Liberal Education Holdings Limited ("China Liberal" or the "Company") (NASDAQ: CLEU), a China-based company that provides technological consulting services...

Yiwu Brands Unite for Overseas Expansion with Grand Opening of Yiwu Selection Store

YIWU, China, Jan. 13, 2025 /PRNewswire/ -- Yiwu, the world's preeminent hub for small commodities, hosts an extensive trading network connecting the globe with...